RVNC - Revance Therapeutics GAAP EPS of -$0.80 misses by $0.01 revenue of $58.13M misses by $0.81M
2023-08-08 16:40:11 ET
- Revance Therapeutics press release ( NASDAQ: RVNC ): Q2 GAAP EPS of -$0.80 misses by $0.01 .
- Revenue of $58.13M (+104.9% Y/Y) misses by $0.81M .
- Q2 RHA Collection revenue of $31.8 million, a YoY increase of 24.7%.
- Q2 DAXXIFY revenue of $22.6 million, a QoQ increase of 47.1%.
- Revance expects 2023 GAAP operating expenses to be $460 million to $480 million and non-GAAP operating expenses, which exclude costs of revenue, depreciation and amortization and stock-based compensation to be $320 million to $340 million.
- Revance expects 2023 non-GAAP research and development expenses to be $80 million to $90 million.
For further details see:
Revance Therapeutics GAAP EPS of -$0.80 misses by $0.01, revenue of $58.13M misses by $0.81M